The technique rests on diffusion-weighted MRI, which sensitizes the MR signal to the random Brownian motion of water molecules. In a typical acquisition, the signal is measured along many diffusion-encoding directions, and a model is fitted to describe how the apparent diffusion coefficient varies with direction. In most brain tissue, diffusion is restricted and anisotropic, meaning water moves more easily along axonal bundles than across them. Free water imaging extends the standard diffusion tensor model by adding an isotropic compartment: a fraction of the voxel’s water is assumed to diffuse freely and equally in all directions, unconstrained by tissue microstructure. The estimated volume fraction of this compartment, often called the free water fraction, is the quantity that studies have linked to Parkinson’s disease.

What the commentary emphasizes is that this seemingly single number is, in practice, the product of a long chain of decisions. Every stage of the pipeline matters: the strength and number of diffusion-encoding gradients, the number of directions acquired, the echo time and voxel size, the correction for head motion and eddy currents, the approach to removing non-brain tissue, the handling of signal dropout, the fitting algorithm used to estimate the free water fraction, and the way regions of interest are defined in the midbrain. Each of these choices can shift the estimated values, and because different studies make different choices, their results are not always directly comparable.

This matters acutely in Parkinson’s disease research because the effect sizes involved are modest. The changes in free water fraction reported between people with Parkinson’s disease and healthy controls are typically small in absolute terms, often on the order of a few tenths of a percent to a few percent of the signal fraction. When the biological signal is that subtle, even small methodological differences can rival or exceed the effect being sought. A pipeline that smooths data aggressively, or that defines the substantia nigra generously, may report group differences where a more conservative pipeline finds none. Conversely, an underpowered or noisy acquisition may obscure real biology. The commentary’s central claim is that free water imaging findings in Parkinson’s disease should therefore be read as conditional statements, valid for a particular acquisition, preprocessing stream, and region-of-interest strategy, rather than as universal truths about the diseased brain.

The stakes are high because free water imaging has been proposed as a candidate imaging biomarker for disease progression and for use in clinical trials. Several longitudinal studies have suggested that free water fraction in the substantia nigra increases over time in people with Parkinson’s disease, raising hopes that the measure could serve as a sensitive endpoint for disease-modifying therapies. If those hopes are to be realized, the field needs to know how much of the measured change reflects biology and how much reflects the measurement apparatus. A biomarker that drifts with scanner software updates, or that responds more strongly to a change in preprocessing than to a change in the disease, cannot support the weight of a multi-center trial.

The commentary also addresses a conceptual trap: the tendency to interpret an elevated free water fraction as a direct, one-to-one readout of neuroinflammation. The biological rationale is plausible, because inflammatory processes such as astrocytic activation and microglial responses can expand the extracellular space and increase the mobility of water. But elevated free water is not specific to inflammation. Edema, enlarged perivascular spaces, tissue atrophy with partial volume effects from cerebrospinal fluid, and even residual artifacts from motion or susceptibility gradients can all inflate the estimate. Treating free water fraction as a binary indicator of an active inflammatory process, present or absent, oversimplifies what is in fact a composite measurement influenced by multiple tissue properties and multiple sources of error.

Partial volume contamination deserves particular attention in the midbrain, where the structures of interest are small and intimately surrounded by cerebrospinal fluid spaces. The substantia nigra lies adjacent to the interpeduncular cistern, and even with careful region-of-interest placement, signal from free cerebrospinal fluid can leak into the measured voxels, especially at the resolutions commonly used in research scanning. Some pipelines attempt to correct for this, while others rely on conservative masking. The commentary suggests that differences in how this problem is handled may explain a substantial portion of the variability in the literature, with some studies reporting robust group differences and others reporting null results for ostensibly similar comparisons.

None of this, the authors are careful to note, amounts to a dismissal of free water imaging. On the contrary, the technique remains one of the most promising MRI-based approaches to the nigral pathology that defines Parkinson’s disease, precisely because it targets a biologically meaningful property of tissue rather than a gross structural change that appears only late in the disease course. The argument is for methodological transparency and rigor: studies should report their acquisition parameters and preprocessing steps in full, share their analysis code where possible, and validate their pipelines against phantom data or across independent datasets. Harmonization efforts across scanning sites, and sensitivity analyses that show how results change under alternative processing choices, would allow the field to distinguish findings that are robust from those that are artifacts of a particular workflow.

For clinicians and trial designers, the practical message is one of calibrated expectations. Free water imaging is not yet a diagnostic test, and a single elevated value in an individual patient should not be read as a verdict on their disease state. The technique’s near-term value lies in group-level comparisons and longitudinal tracking within carefully controlled studies, where its sensitivity to change can be exploited while its methodological dependencies are held constant. As the field moves toward standardization, the commentary argues, the goal should be pipelines whose outputs are stable across sites and scanners, so that the biological signal of neurodegeneration can finally be separated from the technical noise of measurement. In free water imaging, the method is not a mere technicality; it is part of the result itself, and recognizing that is the first step toward turning an intriguing research measurement into a dependable clinical tool.

Subject of Research: The influence of image processing methodology on free water imaging measurements in Parkinson's disease

Article Title: The method matters: free water imaging in Parkinson’s disease is not a binary verdict

Article References: The method matters: free water imaging in Parkinson’s disease is not a binary verdict. (n.d.). https://doi.org/10.1038/s41531-026-01492-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01492-8

Keywords: Parkinson's disease, free water imaging, diffusion MRI, neuroinflammation, biomarkers, image processing, substantia nigra, magnetic resonance imaging, neurodegeneration, methodology, method, matters

The researchers analysed data from the Concussion REcovery STudy, a prospective observational cohort in Perth, Western Australia. Thirty-five adults aged 18 to 65 with a medically diagnosed mTBI were included, alongside 34 age- and sex-matched controls without an mTBI in the previous five years. The injuries were uncomplicated: participants had no acute trauma-related abnormality visible on conventional CT or MRI, had less than 24 hours of post-traumatic amnesia and less than 30 minutes of loss of consciousness. Blood was collected, on average, about five and a half days after injury, and MRI was performed at roughly seven days. Participants then reported their symptoms by telephone at three, six and 12 months.

Blood testing measured several proteins associated with neural injury. NfL is a structural component of axons, the long projections that carry signals between nerve cells. Mechanical forces can stretch axons and disturb their internal scaffolding, allowing NfL fragments to escape into surrounding fluid and eventually enter the bloodstream. The team also measured brain-derived tau, glial fibrillary acidic protein and ubiquitin carboxyl-terminal hydrolase-L1, or UCH-L1, as well as the less commonly studied 4R-tau isoform. UCH-L1 was excluded because the assay results were too variable. Brain-derived tau and GFAP did not differ between groups, possibly in part because those proteins change rapidly after injury and may have returned closer to baseline by the time samples were collected.

NfL and 4R-tau were both higher shortly after mTBI than in controls, although their relationships with later symptoms pointed in opposite directions. Higher NfL was associated with a lower likelihood of still being symptomatic at three months. In the study’s statistical model, NfL correctly classified about three-quarters of participants according to three-month recovery status, but this estimate came from a small sample and does not establish a reliable prediction rule. By contrast, higher 4R-tau was associated with a greater likelihood of symptoms at 12 months and correctly classified about 74 per cent of participants in that analysis. The researchers stress that these results need replication before either marker could guide individual care. The apparently favourable association between higher NfL and recovery may seem counterintuitive. NfL is often treated as a sign of axonal damage, and previous studies have linked higher concentrations with worse outcomes. The authors propose that, in uncomplicated mTBI, a stronger but temporary biological response could sometimes reflect structural remodelling rather than irreversible degeneration. A rise in NfL might therefore accompany a transient disturbance that resolves. But the study collected blood at only one acute timepoint, so it could not determine whether each person’s NfL was rising, peaking or already declining. The result could also reflect chance, unmeasured differences between participants or the small number of people in each recovery group.

4R-tau offers a different biological possibility. Tau proteins help stabilise microtubules, the internal tracks that support axonal transport. The four-repeat form binds particularly strongly to tubulin, but when it detaches it may contribute to microtubule instability, interfere with mitochondrial transport and disrupt calcium regulation. The new study cannot show that 4R-tau caused persistent symptoms. Nevertheless, its selective elevation in participants who remained symptomatic—without a corresponding rise in brain-derived tau—raises the possibility that particular tau isoforms capture processes that total tau measurements miss. The researchers say future studies should directly measure the balance between three-repeat and four-repeat tau, and follow the markers over time.

The MRI results supplied a complementary view of the injury. Diffusion MRI tracks the movement of water molecules through tissue, allowing researchers to infer changes in white-matter organisation that conventional scans may miss. Fractional anisotropy reflects how strongly diffusion follows one direction, as it tends to do along coherent nerve fibres. Mean diffusivity captures the average magnitude of diffusion, while axial and radial diffusivity describe movement along and across the principal fibre direction. These measures are sensitive to microstructural change, but they are not biologically specific: a change can reflect fluid shifts, inflammation, altered cell structure or other processes rather than one identifiable lesion.

Across 48 white-matter tracts, people with mTBI showed widespread increases in radial and axial diffusivity, together with more limited changes in mean diffusivity and fractional anisotropy. The patterns were especially evident in long projection and association fibres, including regions such as the anterior corona radiata, cingulum and superior longitudinal fasciculus. Participants who remained symptomatic at three months had particularly high radial diffusivity in several tracts. Because radial diffusivity is sometimes associated with changes perpendicular to the fibre direction, it can be interpreted as a possible indicator of myelin disruption. In the acute setting, however, the authors consider disturbed ion balance, extracellular fluid and inflammatory processes more plausible than overt demyelination. Mean diffusivity showed a contrasting pattern. Participants who later recovered had higher acute mean diffusivity than controls across several association-fibre regions, and higher mean diffusivity in the left superior longitudinal fasciculus was associated with a lower likelihood of symptoms at six months. The relationship persisted in a model of 12-month status, although the wording of the statistical result indicates an inverse association rather than a proven protective effect. Recovered participants also showed relationships between NfL and mean diffusivity in the right cerebral peduncle, while lower 4R-tau was associated with higher axial diffusivity in the right posterior thalamic radiation among those recovered at 12 months. No corrected blood–MRI correlations emerged in the symptomatic group, perhaps reflecting greater biological heterogeneity or processes outside white matter.

The study also examined whether resilience and coping style changed the links between acute biology and later symptoms. A general measure of resilience did not distinguish injured participants from controls and did not significantly moderate the principal biomarker relationships. Coping patterns did. Passive reaction coping significantly altered the association between NfL and three-month outcome: the inverse relationship between NfL and persistent symptoms was strongest among participants reporting more passive coping. Reassuring-thought coping similarly moderated the relationship between 4R-tau and 12-month symptoms; higher 4R-tau was associated with greater odds of persistent symptoms when this coping style was less frequently used. These findings do not mean that a particular coping strategy causes recovery or that people can think their way out of brain injury. Coping may reflect premorbid traits, stress biology, illness perceptions or the effects of early symptoms, and the analyses were explicitly hypothesis-generating.

Several limitations make the results a starting point rather than a diagnostic breakthrough. The cohort was small, with follow-up numbers falling to 31 participants at six and 12 months. Participants were classified as recovered or symptomatic using self-reported Post-Concussion Symptom Scale scores, so the outcome necessarily reflected subjective experience; symptoms also occur in the general population. Recovery-group membership could change from one follow-up to another, making long-term trajectories difficult to interpret. The study used a single acute blood and MRI assessment, lacked pre-injury measurements of resilience and coping, and included multiple statistical comparisons despite limited power. Diffusion metrics cannot by themselves identify the underlying tissue process, and the blood assays for 4R-tau and brain-derived tau are not directly interchangeable.

Even with those caveats, the results point toward a more nuanced way to study mTBI. Instead of treating every concussion as biologically equivalent, researchers could combine clinical assessment with molecular markers, microstructural imaging and personal context. The next tests will require larger prospective cohorts, repeated blood sampling and serial diffusion MRI, ideally with pre-injury data in groups such as athletes at elevated risk. Studies should determine whether NfL and 4R-tau follow distinct time courses, whether tau-isoform balance predicts symptoms independently of initial symptom burden, and whether the MRI patterns replicate across different injury mechanisms and healthcare settings. For now, the central message is not that a blood test can forecast an individual’s future, but that the early biology of mTBI may contain several different stories—some associated with resolution, others with symptoms that persist.

Subject of Research: Mild traumatic brain injury, blood-based biomarkers, diffusion MRI and recovery trajectories.

Article Title: Divergent recovery trajectories after mild traumatic brain injury are characterized by distinct acute profiles of neurofilament light, 4R-tau, and white matter diffusivity.

Article References: Original article in the Journal of Neurology.

DOI: 10.1007/s00415-026-14060-0

Keywords: Mild traumatic brain injury; post-concussion symptoms; blood biomarkers; diffusion magnetic resonance imaging; psychological resilience; coping skills.

Alzheimer’s disease, a devastating neurodegenerative condition characterized by cognitive decline and memory loss, remains elusive to effective disease-modifying therapies. The enzyme OGA has emerged as a potential therapeutic target due to its role in modulating protein O-GlcNAcylation, a post-translational modification implicated in tau protein stabilization and aggregation. Ceperognastat’s design aimed at selectively inhibiting OGA to restore normal tau processing and reduce neurofibrillary tangles, pathological hallmarks of Alzheimer’s disease.

The clinical trial enrolled individuals exhibiting early symptomatic stages of Alzheimer’s and administered Ceperognastat orally over a defined treatment period. Researchers meticulously monitored cognitive function, biomarkers of neurodegeneration, and safety profiles. Although the pharmacodynamic effects confirmed OGA inhibition, the study did not demonstrate statistically significant slowing in the progression of clinical symptoms or measurable changes in disease biomarkers compared to placebo.

These findings underscore the complexity of Alzheimer’s pathophysiology and highlight challenges in translating biochemical targets into effective therapies. While Ceperognastat successfully modulated a key enzymatic pathway involved in tau pathology, this intervention alone appears insufficient to alter the clinical trajectory of early symptomatic Alzheimer’s disease meaningfully.

The study’s outcome offers crucial insights for the medical and scientific community by refining the understanding of molecular targets necessary for successful intervention. It suggests that future research may require combination therapies or targeting additional pathological mechanisms alongside OGA inhibition to achieve therapeutic benefits.

Furthermore, this trial exemplifies the importance of rigorous clinical evaluation and the need for innovative approaches in Alzheimer’s drug development. Despite disappointment at the lack of efficacy, the data contribute to a growing landscape of knowledge essential for guiding the next generation of therapeutic strategies.

As Alzheimer’s disease continues to pose a profound global health challenge, the search for effective disease-modifying treatments remains urgent. This study, presented in conjunction with the Alzheimer’s Association International Conference, reinforces both the progress made and the hurdles ahead in conquering this formidable neurological disorder.

Although Ceperognastat’s journey as a monotherapy in early symptomatic Alzheimer’s has not yielded the hoped-for clinical benefits, ongoing research will build on this foundation to explore synergistic combinations and novel targets in the fight against neurodegeneration.

Subject of Research: Alzheimer’s disease, O-linked N-acetylglucosaminidase inhibition, neurodegenerative disease treatment
Article Title: Not provided
News Publication Date: Not provided
Web References: Not provided
References: (doi:10.1001/jama.2026.12768)
Image Credits: Not provided
Keywords: Alzheimer disease, symptomatology, inhibitory effects, small molecules, disease progression, medical treatments